



## Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT® Code Change Applications May 2024 Editorial Panel Meeting

Pathology/Laboratory and Molecular Pathology/MAAA/GSP CPT Code Change Applications (CCAs) that have been submitted for consideration by the CPT Editorial Panel at its May 2024 meeting are listed below. These applications will also be included in the proposed Panel agenda that will be posted to the AMA website on March 1, 2024. This listing includes the code application names, code(s) affected, and a description of the request. **Until such time as the CPT Editorial Panel acts on these requests, the following information is provided for informational purposes only, giving interested individuals the information to help determine whether or not to attend the meeting and provide comment on a given topic(s).**

This listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP applications is being posted ahead of the full February Panel meeting agenda in order to provide the Molecular Pathology Advisory Group (MPAG) and the Pathology Coding Caucus (PCC) sufficient time to review comments from interested stakeholders prior to making their recommendations to the CPT Editorial Panel.

Codes that contain an 'X' (e.g., 10X24, 23X42, 03X0T) below are temporary codes that are intended to give readers an idea of the proposed placement in the code set of the potential code changes. **These temporary codes are not used for claims reporting and will be removed and not retained when the final CPT Datafiles are distributed on August 31<sup>st</sup> of each year. To report the services described by the "X" codes listed on this form, please refer to the actual codes as they appear in the CPT Datafiles publication distributed on August 31<sup>st</sup> of the corresponding year.**

### **NOTICE –INTERESTED PARTY PROCESS**

Upon review of this agenda, if the reviewer believes that they will need to provide comment on an issue, they must seek Interested Party status by [submitting a request](#) for a copy of the application and associated materials. **Requests are to be submitted through the Smart App's CPT Interested Party dashboard.** Those interested in review of the agenda materials are required to complete this form in full.

Any interested parties wishing to provide written comments on any agenda items should be aware of the following relevant deadlines for provision of written comments on the agenda to ensure comment review by all parties. Additional verbal comments on any issue can be provided in person at the Panel meeting following a statement of conflict of interest. The applicant(s) who submitted the original code change application is automatically considered an interested party and is notified by AMA staff of any request for review submitted by another party.

Updated February 26, 2024

- New
- ▲ Revision
- ⊕ Add on
- D Deletion



\*Interested party requests will not be processed until the interested party submits a signed confidentiality agreement and disclosure of interest form. Please follow the instructions in the correspondence that accompanies the materials.

<b>Pathology/Laboratory and Molecular Pathology, Multianalyte Assays with Algorithmic Analyses, and Genomic Sequencing Procedures Deadlines for Interested Stakeholders</b>	
<b>Request for Code Change Application Materials</b>	<b>February 29, 2024</b>
<b>Submission of Written Comments</b>	<b>March 4, 2024</b>

During the time between now and the Panel meeting, this listing of Pathology/Laboratory and Molecular Pathology/MAAA/GSP CCAs may be modified to reflect changes – additions, deletions or updates. Please check back frequently for the most up to date information. Outcomes on these actions will be listed in the CPT Editorial Panel Summary of Actions for the May 2024 meeting, which will be published on or before June 7, 2024 to the CPT home page of the AMA website <http://www.ama-assn.org/go/panel-actions>.

<b>Name</b>	<b>Code #</b>	<b>Request-Description</b>
MAAA-Bacterial Vaginosis-Vaginitis	● 8XX00	Establish Category I Multianalyte Assays with Algorithmic Analyses (MAAA) code 8XX00 for bacterial vaginosis and vaginitis associated diseases.

Updated February 26, 2024

- New
- ▲ Revision
- ⊕ Add on
- D Deletion

Name	Code #	Request-Description
Neurofilament Light Chain	● 83XX0	Establish a Category I code 83XX0 to report Neurofilament light chain (NFL).
Admin MAAA-Fibrosis and NASH	● 0X01M	Establish Administrative Multianalyte Assays with Algorithmic Analyses (MAAA) code 0X01M to identify algorithmic analysis of twelve standard testing procedures for patients at high risk for Nonalcoholic Steatohepatitis (NASH) and fibrosis.
Pneumocystis Jirovecii Amp Probe Technique	● 87XX0	Establish Category I code 87XX0 to report pneumocystis jirovecii by amplified probe technique.
Optical Genome Mapping	● 88XX0	Establish Category I code 88XX0 to identify optical genome mapping method of cytogenomic chromosomal abnormalities.
Cellular Enrichment by Immunomagnetic Selection	● 88XX1	Establish Category I code 88XX1 to report cellular enrichment by immunomagnetic selection for ISH.
HPV Combined Reporting Pooled and Individual Genotyping Results	D0500T ● 87XX1	Establish Category I code 87XX1 to report high-risk types of Human Papillomavirus (HPV) and delete Category III code 0500T.
Streptococcus Pneumoniae Antibody	● 86XX1	Establish Category I code 86XX1 to report streptococcus pneumoniae.
Cytokine Panel	● 82XX2	Establish 82XX2 to report cytokine type testing and quantities in blood to monitor various immune inflammatory/disease conditions.
GSP-Carrier Genetic Testing	▲ 81412 ▲ 81443	Revise codes 81412 and 81443 to describe carrier genetic testing for heritable conditions.

Name	Code #	Request-Description
GSP-Hereditary Cancer Disorders, Cancer Predisposition	▲81432 D81433 ▲81435 D81436 ▲81437 D81438 ●81X01	Revise codes 81432, 81435, and 81437, delete code 81433, 81436, and 81438, and establish code 81X01 for testing of hereditary cancer disorders.